Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
作者信息
Zhang Yana, Wang Zhiqing, Zhang Jian, Farmer Benjamin, Lim Seah H
机构信息
Cancer Research Program, Harrington Regional Medical Center, Amarillo, TX, USA.
出版信息
Leuk Res. 2008 Dec;32(12):1889-94. doi: 10.1016/j.leukres.2008.03.036. Epub 2008 May 12.
Abstract
Semenogelin (SEMG) I is a Cancer-Testis (CT) antigen that we have found to be expressed in myeloma cells. In this study, we set out to determine whether the expression of SEMG I could be upregulated pharmacologically. We found that SEMG I expression in myeloma cells can be upregulated by 5-azacytidine, IL-4 and IL-6. The mechanisms of SEMG I gene upregulation by 5-azacytidine is unclear since there was no correlation between the methylation of the single CpG dinucleotide at position -11 and SEMG I expression. Both IL-4 and IL-6 appeared to enhance SEMG I expression through increasing its promoter function.
摘要
相似文献
1
Semenogelin I expression in myeloma cells can be upregulated pharmacologically.
Leuk Res. 2008 Dec;32(12):1889-94. doi: 10.1016/j.leukres.2008.03.036. Epub 2008 May 12.
2
Core promoter sequence of SEMG I spans between the two putative GATA-1 binding domains and is responsive to IL-4 and IL-6 in myeloma cells.
Leuk Res. 2009 Jan;33(1):166-9. doi: 10.1016/j.leukres.2008.05.021. Epub 2008 Jul 7.
3
SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically.
Int J Cancer. 2006 Mar 15;118(6):1436-44. doi: 10.1002/ijc.21499.
4
Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies.
J Immunother. 2003 Nov-Dec;26(6):461-7. doi: 10.1097/00002371-200311000-00001.
5
SPAN-XB core promoter sequence is regulated in myeloma cells by specific CpG dinucleotides associated with the MeCP2 protein.
Int J Cancer. 2006 Dec 15;119(12):2878-84. doi: 10.1002/ijc.22259.
6
[5-azacytidine treatment induces tumor suppressor gene XAF1 expression and inhibits proliferation in myeloma cells].
Zhonghua Xue Ye Xue Za Zhi. 2009 Apr;30(4):229-32.
7
Association of semenogelin (SEMG) gene variants in idiopathic male infertility in Chinese-Han population.
J Toxicol Environ Health A. 2019;82(16):928-934. doi: 10.1080/15287394.2019.1669304. Epub 2019 Sep 19.
8
Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma.
Epigenetics. 2011 Aug;6(8):1047-52. doi: 10.4161/epi.6.8.16167. Epub 2011 Aug 1.
9
Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells.
Int J Oncol. 1999 Jul;15(1):173-8. doi: 10.3892/ijo.15.1.173.
10
Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation.
Cancer Res. 2005 Jun 1;65(11):4673-82. doi: 10.1158/0008-5472.CAN-04-3589.
引用本文的文献
1
Emerging roles of cancer-testis antigenes, semenogelin 1 and 2, in neoplastic cells.
Cell Death Discov. 2021 May 8;7(1):97. doi: 10.1038/s41420-021-00482-4.
2
Identification of Urinary Biomarkers for Exercise-Induced Immunosuppression by iTRAQ Proteomics.
Biomed Res Int. 2020 Jan 23;2020:3030793. doi: 10.1155/2020/3030793. eCollection 2020.
3
The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
Cancer Immunol Immunother. 2017 Jun;66(6):697-703. doi: 10.1007/s00262-017-1990-2. Epub 2017 Mar 24.
4
Azacytidine induces necrosis of multiple myeloma cells through oxidative stress.
Proteome Sci. 2013 Jun 13;11(1):24. doi: 10.1186/1477-5956-11-24.
5
Body fluid identification by mass spectrometry.
Int J Legal Med. 2013 Nov;127(6):1065-77. doi: 10.1007/s00414-013-0848-1. Epub 2013 Mar 24.
6
Cancer-testis antigens: the current status on antigen regulation and potential clinical use.
Am J Blood Res. 2012;2(1):29-35. Epub 2012 Jan 1.
7
Core promoter sequence of SEMG I spans between the two putative GATA-1 binding domains and is responsive to IL-4 and IL-6 in myeloma cells.
Leuk Res. 2009 Jan;33(1):166-9. doi: 10.1016/j.leukres.2008.05.021. Epub 2008 Jul 7.
本文引用的文献
1
SPAN-XB core promoter sequence is regulated in myeloma cells by specific CpG dinucleotides associated with the MeCP2 protein.
Int J Cancer. 2006 Dec 15;119(12):2878-84. doi: 10.1002/ijc.22259.
2
Characterization of semenogelin proteins in the human retina.
Exp Eye Res. 2006 Jul;83(1):120-7. doi: 10.1016/j.exer.2005.11.011. Epub 2006 Mar 20.
3
Expression of seminal vesicle-specific antigen in serum of lung tumor patients.
J Forensic Sci. 2005 Sep;50(5):1114-5.
4
SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically.
Int J Cancer. 2006 Mar 15;118(6):1436-44. doi: 10.1002/ijc.21499.
5
Sp17 gene expression in myeloma cells is regulated by promoter methylation.
Br J Cancer. 2004 Oct 18;91(8):1597-603. doi: 10.1038/sj.bjc.6602160.
6
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 2004 May 27;429(6990):457-63. doi: 10.1038/nature02625.
7
Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies.
J Immunother. 2003 Nov-Dec;26(6):461-7. doi: 10.1097/00002371-200311000-00001.
8
Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues.
Mol Hum Reprod. 2002 Sep;8(9):805-10. doi: 10.1093/molehr/8.9.805.
9
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
Oncogene. 2002 Aug 12;21(35):5427-40. doi: 10.1038/sj.onc.1205600.
10
Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications.
Br J Cancer. 2002 Mar 18;86(6):979-82. doi: 10.1038/sj.bjc.6600174.
Zotero 插件